This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	Lysine-specific demethylase 2A (KDM2A; JHDM1A)	<p>Patient sample, cell culture and mouse studies suggest decreasing levels of KDM2A could help treat NSCLC. In patient NSCLC tumor samples, KDM2A mRNA and protein levels were higher than those in normal lung tissue samples and correlated with poor survival. In NSCLC cell lines expressing high levels of KDM2A, siRNA against <i>KDM2A</i> decreased cell proliferation and invasiveness compared with control siRNA. In mice injected with NSCLC cells with high KDM2A levels, pretreatment with siRNAs against <i>KDM2A</i> led to no lung tumors, whereas control siRNA pretreatment led to multiple lung tumors. Next steps include using lung-specific knockout or transgenic mouse models to provide genetic evidence that KDM2A promotes NSCLC.</p> <p>SciBX 6(47); doi:10.1038/scibx.2013.1345 Published online Dec. 12, 2013</p>	Patent application filed; available for licensing	<p>Wagner, K.W. <i>et al. J. Clin. Invest.</i>; published online Nov. 8, 2013; doi:10.1172/JCI68642</p> <p>Contact: Min Gyu Lee, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: mglee@mdanderson.org</p>